Abstract:The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023-24. However, the increase in infections was not accompanied by increases in COVID-19 hospitalizations and mortality commensurate with prior waves. To understand shifts in COVID-19 epidemiology associated with JN.1 emergence, we compared characteristics and clinical outcomes of time-matched cases infected with BA.2.86- derived lineages (predominantly representing JN.1) versus co-circulating XBB-derived lineages in December, 2023 and January, 2024. Cases infected with BA.2.86-derived lineages received greater numbers of COVID-19 vaccine doses, including XBB.1.5-targeted and BA.4/BA.5-targeted boosters, in comparison to cases infected with XBB-derived lineages. Additionally, cases infected with BA.2.86-derived lineages experienced greater numbers of documented prior SARS-CoV-2 infections. These associations of BA.2.86-derived lineages with immune escape were confirmed when comparing cases diagnosed during periods when JN.1 was the predominant circulating lineage to cases diagnosed during November, 2023. Cases infected with BA.2.86-derived lineages, or during periods when JN.1 was the predominant circulating lineage, also experienced lower risk of progression to severe clinical outcomes requiring emergency department consultations or hospital admission. Sensitivity analyses suggested under-ascertainment of prior infections, even if differential between cases infected with BA.2.86-derived lineages and non-BA.2.86 lineages, could not explain this apparent attenuation of severity. Our findings implicate escape from immunity acquired from prior vaccination or infection in the emergence of the JN.1 lineage and suggest infections with this lineage are less likely to experience clinically-severe disease. Monitoring of immune escape and clinical severity in emerging SARS-CoV-2 variants remains a priority to inform responses.

SARS-CoV-2 JN.1 reveals attenuated pathogenicity and airborne transmission

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3

Virological characteristics of the SARS-CoV-2 JN.1 variant

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

Virological characteristics of SARS-CoV-2 Omicron BA.5.2.48

Omicron XBB.1.5 subvariant causes severe pulmonary disease in K18-hACE-2 mice

Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology

Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 sublineage, including HK.3 and EG.5.1

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Genomic epidemiology reveals early transmission of SARS-CoV-2 and mutational dynamics in Nanning, China

Human Airway and Nasal Organoids Reveal Escalating Replicative Fitness of SARS-CoV-2 Emerging Variants.

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract

SARS-CoV-2 JN.1 variant: a short review

Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage

Evolving Immune Evasion and Transmissibility of SARS-CoV-2: the Emergence of JN.1 Variant and Its Global Impact.

Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters

The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.

Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates